| Catalogue number: | PA 21 0250000 |
| Chemical name: | Ubrogepant |
CAS Number: |
1374248-77-7 |
| Category: | metabolites,pharmaceutical standards,intermediates,Fine Chemicals |
| Synonyms: | (S)-N-((3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide; (3′S)-1′,2′,5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxospiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide; Ubrelvy; |
| Molecular form: | C29H26F3N5O3 |
| Appearance: | NA |
| Mol. Weight: | 549.55 |
| Storage: | 2-8°C Refrigerator |
| Shipping Conditions: | Ambient |
| Applications: | Ubrogepant is an oral CGRP antagonist used in the acute treatment of migraine with or without aura.Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults.5 It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.6 Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and rimegepant remain in clinical development |
Ubrogepant - API Standards
Ubrogepant
Enquire for Ubrogepant - API Standards
Order Product
Related Products
EVENTS
Search by Keywords – Buy 1374248-77-7 | Purchase 1374248-77-7 | Order 1374248-77-7 | Enquire 1374248-77-7 | Price of 1374248-77-7 | 1374248-77-7 Cost | 1374248-77-7 Supplier | 1374248-77-7 Distributor | 1374248-77-7 Manufacturer | 1374248-77-7 Exporter
